Pulmonary arterial hypertension (PAH) is a rare, progressive disorder impacting small pulmonary arteries, leading to increased vascular resistance and heart failure. The latest report forecasts ...

The disease primarily affects middle-aged women and has a poor long-term prognosis despite therapeutic advances.

The company will use the funds for a European feasibility study for its transcatheter device and for the launch of a ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM) is projected to reach $9.3b by 2034, ...

Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

Endothelial dysfunction markers were linked to future disease activity and complications in lcSSc.

UBS analyst Ashwani Verma maintained a Buy rating on United Therapeutics (NASDAQ:UTHR) on June 30 but adjusted the price ...

Memorial Using Tech to Help Patients Monitor Vitals at Home A 30-second, at-home test can alert those with pre-existing cardiac conditions to abnormalities within their heart before the onset of any ...

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK ...